Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review

Abstract Pancreatic cancer is an extremely malignant tumor with the lowest 5-year survival rate among all tumors. Pancreatic ductal adenocarcinoma (PDAC), as the most common pathological subtype of pancreatic cancer, usually has poor therapeutic results. Immune checkpoint inhibitors (ICIs) can relie...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hong-Bo Li, Zi-Han Yang, Qing-Qu Guo
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
R
Acceso en línea:https://doaj.org/article/406634dabe0244e6958f3f3e3ac6d2be
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares